Module 4 · Quality & Safety Documentation

Digital Quality & Safety Documentation in Pharmaceutical Manufacturing

Act as the Quality Assurance officer for a batch of Paracetamol 500 mg tablets: review the Batch Manufacturing Record, verify raw materials and QC results, record a deviation and its CAPA, assess recall risk, and make an evidence-based GMP batch-release decision. Duration 3 hours.

Score —
Result —
◐ Theme

New to GMP documentation? Start here

In manufacturing, "not documented = not done." A batch is released on the strength of its records, not on how the tablets look. Your job is to prove — with complete, in-specification, signed documentation — that this batch is safe to release.

  1. Review the BMR — every entry present, correct, calculated and signed.
  2. Verify materials against their Certificate of Analysis.
  3. Judge each result against its specification, not by eye.
  4. Record the deviation, its root cause and risk; raise CAPA.
  5. Assess recall risk from complaints, then Release / Hold / Reject with justification.

Your batch

ProductParacetamol 500 mg Tablets
Batch numberPCM-500-2607
Manufactured18 July 2026
ExpiryJuly 2028
Batch size100,000 tablets
Your roleQuality Assurance (QA) Officer

Assessment rubric (100 marks)

ComponentMarks
Batch Manufacturing Record review15
Raw-material verification10
In-process & QC documentation20
Deviation & CAPA documentation20
Batch-release decision15
Digital dashboard & graphs10
Workflow diagram & QR code5
Report quality & documentation5
Total100
Critical failure: releasing the batch while a deviation is open, a QC result fails, or documentation is incomplete fails the practical regardless of marks — exactly as it would trigger a regulatory action in a real facility.
15 marksStep 1 · Batch Manufacturing Record

Review the BMR for completeness and accuracy

FieldBMR entry
Product nameParacetamol 500 mg Tablets
Batch numberPCM-500-2607
Manufacturing date18 July 2026
Expiry dateJuly 2028
Batch size100,000 tablets
Equipment usedCompression machine CM-04 (calibrated)
Operator signatureS. Kumar ✓
QA signature— missing —
1.1 Which record issues can you identify? (tick all that apply)
1.2 Can the batch be released while a required signature is missing from the BMR?
10 marksStep 2 · Raw-material verification

Verify each material against its Certificate of Analysis

MaterialSupplierBatchCoAExpiry
Paracetamol APIPharmaChem LtdPA-2231Present2027
Starch (binder)ExciCorpST-8842Present2027
Magnesium stearateLubriPharmMG-1190Missing2026
2.1 Magnesium stearate arrived without a Certificate of Analysis. What is the correct action?
2.2 Why must every raw material be verified before use?
20 marksSteps 3 & 4 · In-process & QC results

Judge every result against its specification

ParameterSpecificationResultVerdict
Tablet weight650 ± 5% mg648 mgPass
Hardness5–8 kg/cm²6.2Pass
Friability< 1%0.45%Pass
Disintegration< 15 min9 minPass
Assay95–105%99.2%Pass
Dissolution≥ 80% in 30 min94%Pass
Content uniformityWithin limitsCompliesPass
Microbial limitWithin limitsCompliesPass
3.1 Do the in-process and QC results meet all specifications?
3.2 Tablet weight is 648 mg against 650 ± 5% mg. Is that within specification?
part of Deviation & CAPAStep 5 · Deviation report

Record the production deviation

Deviation: during compression, the machine speed exceeded the approved limit for 12 minutes.
Root-cause analysis
Product risk assessment
Immediate action taken
20 marks (with Step 5)Step 6 · CAPA

Corrective and Preventive Action

Corrective action (fix this occurrence)
Preventive action (stop it recurring)
6.1 What is the essential difference between corrective and preventive action?
recall riskStep 7 · Recall risk assessment

Three complaints of tablet breakage received

7.1 Given complaints of breakage on a batch with an open deviation, what should you do? (tick all that apply)
Document your recall decision & justification
15 marksStep 8 · Batch-release decision

Make the QA decision on the full record set

Consider: QA signature missing on the BMR · magnesium stearate CoA missing · an open compression-speed deviation · complaints of breakage under investigation. QC results themselves are in specification.

8.1 What is the correct batch-release decision now?
Scientific justification for your decision
You can revise your answers and re-evaluate.

Digital documents & visualisation 15 marks

Alongside your report, prepare and attach the following. Tick each once done.

Documents to generate

1 · Production quality dashboard part of 10

Your live figures — rebuild this as your own dashboard.

2 · QC trend graph part of 10

Assay (%) across recent batches — reproduce and mark the 95–105% specification band.

3 · Batch workflow diagram part of 5

Raw material receipt
▼
Quality inspection
▼
Manufacturing
▼
In-process quality check
▼
Quality control testing
▼
Deviation review → CAPA
▼
QA approval
▼
Batch release → Market distribution

4 · Traceability QR code part of 5

Generate a real QR linking to the batch record: product name · batch number · manufacturing & expiry dates · QC status · release status · CoA · traceability information.

The block is a layout simulation — generate a genuine scannable QR with any generator.

5 · Optional 1-minute animation

Raw-material inspection → manufacturing → quality testing → documentation → batch approval → product release.

Reflection on quality & patient safety

Your result

Complete the QA Documentation station and press Evaluate to see your score breakdown here.

Reflection questions

  1. Why is "not documented = not done" a core GMP principle?
  2. What is the difference between QA and QC?
  3. What must a deviation report contain?
  4. How do corrective and preventive actions differ?
  5. Why can a batch with passing QC still be held?
  6. When is a product recall required?
  7. Why must every raw material carry a Certificate of Analysis?
  8. How does batch traceability enable a rapid recall?
  9. Who is authorised to release a batch, and on what basis?
  10. How does digital documentation improve GMP compliance?